Back to Authors

Alberts, Steven R.

https://orcid.org/0000-0002-5835-4122

Mayo Clinic

Mayo Clinic

Citations 198

RUCAPANC: An open-label, phase 2 trial of the PARP inhibitor rucaparib in patients (pts) with pancreatic cancer (PC) and a known deleterious germline or somatic BRCA mutation.
Hendifar, Andrew , Geva, Ravit , Epelbaum, Ron, Vonderheide, Robert H. , Wolff, Robert A. , Giordano, Heidi, Goble, Sandra, Shroff, Rachna T. , Domchek, Susan M. , McWilliams, Robert R. , Biankin, Andrew V. , Alberts, Steven R. , Lin, Kevin

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 4110-4110

10.1200/jco.2016.34.15_suppl.4110 Get It

Association of adverse events (AEs) with outcomes in early stage colon cancer (CC): An analysis of 10,695 CC patients from the ACCENT database.
Grothey, Axel, Haller, Daniel G. , Gramont, Aimery de , Twelves, Christopher , Goldberg, Richard M. , Cheung, Winson Y. , André, Thierry , Kerr, Rachel , Dixon, Jesse G. , Alberts, Steven R. , O’Connell, Michael J. , Saltz, Leonard B. , Lonardi, Sara , Yoshino, Takayuki , Yothers, Greg , Shi, Qian

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 3601-3601

10.1200/jco.2018.36.15_suppl.3601 Get It

Validation of tumor infiltrating lymphocytes (TIL) and tumor budding as predictors of prognosis in patients with stage III colon cancers treated in a FOLFOX-based adjuvant trial: NCCTG N0147 (Alliance).
Lee, Hee Eun , Foster, Nathan R. , Smyrk, Thomas C. , Sinicrope, Frank A. , Shi, Qian , Alberts, Steven R.

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 3583-3583

10.1200/jco.2018.36.15_suppl.3583 Get It

Association of sex and adverse events (AEs) of adjuvant chemotherapy (ACT) in early stage colon cancer (CC): A pooled analysis of 28,636 patients (pts) in the ACCENT database.
Haller, Daniel G. , Allegra, Carmen J. , VanCutsem, Eric, Gramont, Aimery de , Twelves, Chris, Blanke, Charles D. , Francini, Guido, Goldberg, Richard M. , Wagner, Dorothea , Grothey, Axel , André, Thierry , Dixon, Jesse G. , Wolmark, Norman , George, Thomas J. , Alberts, Steven R. , O’Connell, Michael J. , Saltz, Leonard B. , Kerr, Rachel , Yothers, Greg , Shi, Qian

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 3603-3603

10.1200/jco.2018.36.15_suppl.3603 Get It

CD3+ and CD8+ tumor-infiltrating lymphocyte (TIL) densities to prognostically stratify DNA mismatch repair-deficient (dMMR) colon cancer patients (pts): NCCTG N0147 (Alliance).
Yoon, Harry H. , Heying, Erica N., Murányi, Andrea , Ough, Faith , Djalilvand, Azita, Clements, June, Bowermaster, Rebecca, Shanmugam, Kandavel , Shi, Qian , Liu, Wenwei , Barnes, Michael, Alberts, Steven R. , Sinicrope, Frank A.

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 3598-3598

10.1200/jco.2018.36.15_suppl.3598 Get It

Genome-wide association with survival in stage II-III colon cancer clinical trials (NCCTG N0147, Alliance for Clinical Trials in Oncology; NSABP C-08, NRG Oncology).
Banbury, Barbara L. , Allegra, Carmen J. , Peters, Ulrike , Nair, Suresh , Harrison, Tabitha A. , Goldberg, Richard M. , Lucas, Peter C. , Colangelo, Linda H., Atkins, James N., Harrison, Tabitha A , Lucas, Peter C , Penney, Kathryn , Shi, Qian , Alberts, Steven R. , Yothers, Greg , Sinicrope, Frank A. , Sun, Wei , Newcomb, Polly A. , Chan, Andrew T.

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 3582-3582

10.1200/jco.2018.36.15_suppl.3582 Get It

Abstract 4239: Infection, inflammation and cancer: Understanding Alaska Native cancer health disparities
Olnes, Matthew J. , Martinson, Holly , Alberts, Steven R.

Cancer Research | August 17, 2018 | Volume: 78 | Issue: 13_Supplement | Pages: 4239-4239

10.1158/1538-7445.am2018-4239 Get It

Abstract Gastric cancer is a leading cancer health disparity among the Alaska Native (AN) people, occurring at a 3-fold higher incidence and 4-fold higher mortality rate in comparison to U.S. Non-Hispanic whites (NHW). AN gastric cancer patients have significant differences in tumor location and appearance compared to NHW patients. In addition, AN patients are younger at the time of diagnosis, 60 versus 69 years and have a lower 5-year survival rate of 10% compared to 22% of NHW gastric cancer patients. The purpose of this research was to understand the role of gene mutations, inflammation, and infection as possible factors in the promotion of gastric cancer in the AN population. In this study, we examined previously obtained tissue samples from AN gastric cancer patients diagnosed between 2006-2014 at the Alaska Native Medical Center. Using next-generation sequencing, immunohistochemistry and in situ hybridization, we evaluated for 50 cancer related gene mutations, the presence of the virus, Epstein-Barr virus (EBV), the bacterium, Helicobacter pylori (H. pylori), and inflammatory factors. Cancer related gene mutations were observed in 69% of gastric tumors from AN patients. The most commonly mutated genes were TP53 (30%), PIK3CA (13%), STK11 (6%), KRAS (5%), and PTEN (5%). Of particular interest, gene mutations were associated with patients who were younger at time of diagnosis (less than 55 years old) and had a history of chronic gastritis. Additionally, EBV is associated with 23% of AN gastric cancers, which is significantly higher than the 10% of EBV associated gastric cancer cases observed in other populations. EBV associated AN gastric cancer patients were more likely to have a history of chronic gastritis, prior or current H. pylori infection, and tobacco use. Notably, aberrant overexpression of the inflammatory factor cyclooxygenase 2 (COX-2) and the glycoprotein Mucin 1 (MUC1) in gastric cancer cells was significantly associated with a poorer prognosis among AN gastric cancer patients. Collectively, these findings indicate infection and inflammation are potential driving factors in the pathogenesis of gastric cancer among the AN people, which may have important clinical implications. Citation Format: Holly Martinson, Steven Alberts, Matthew Olnes. Infection, inflammation and cancer: Understanding Alaska Native cancer health disparities [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 4239.
Survival and Prognostic Factors in Patients With Solid Pseudopapillary Neoplasms of the Pancreas
Huffman, Brandon M. , Westin, Gustavo Figueiredo Marcondes, Alsidawi, Samer , Nagorney, David M. , Hálfdánarson, Þorvarður R. , Mahipal, Amit , Mahipal, Amit , Halfdanarson, Thorvardur R , Alberts, Steven R.

Pancreas | July 23, 2018 | Volume: 47 | Issue: 8 | Pages: 1003-1007

10.1097/mpa.0000000000001112 Get It

Objectives Prognostic factors for solid pseudopapillary neoplasms (SPN) of the pancreas have been incompletely defined in the literature. We aimed to use the National Cancer Database to describe survival and characterize prognostic factors in patients with pancreatic pseudopapillary neoplasms. Methods We identified 304 patients with pancreatic SPN diagnosed between 2004 and 2012 using the National Cancer Database. All patients were included in the survival analysis. Kaplan-Meier method, χ 2 , and log-rank tests were used for statistical analysis. Cox proportional hazard regression model was used for multivariate analysis. Results The median age at diagnosis was 36.5 years. Eighty-five percent of patients were female, 69% were white, and 25% were black. Metastases were observed in 5% of patients. Median tumor size was 5.1 cm. Ninety-two percent of patients underwent primary tumor resection. At 60 months, 98% of patients who underwent resection were alive, and 40% who did not undergo resection were alive. On multivariate analysis, female sex, resection of primary tumor, and absence of metastasis were correlated with improved survival. Conclusions Patients with SPN who undergo resection have an excellent survival at 5 years. Surgery should be considered in all patients with this diagnosis.
Physical Activity and Outcomes in Patients with Stage III Colon Cancer: A Correlative Analysis of Phase III Trial NCCTG N0147 (Alliance)
Phipps, Amanda I. , Shi, Qian , Dotan, Efrat , Goldberg, Richard M. , Hardikar, Sheetal , Jahagirdar, Balkrishna, Shields, Anthony F. , Zemla, Tyler J, Limburg, Paul J. , Shi, Qian , Zemla, Tyler , Gill, Sharlene , Newcomb, Polly A. , Sinicrope, Frank A. , Sargent, Daniel J. , Alberts, Steven R.

Cancer Epidemiology, Biomarkers & Prevention | March 21, 2018 | Volume: 27 | Issue: 6 | Pages: 696-703

10.1158/1055-9965.epi-17-0769 Get It

AbstractBackground: Prior studies have supported an inverse association between physical activity and colon cancer risk and suggest that higher physical activity may also improve cancer survival. Among participants in a phase III adjuvant trial for stage III colon cancer, we assessed the association of physical activity around the time of cancer diagnosis with subsequent outcomes.Methods: Before treatment arm randomization (FOLFOX or FOLFOX + cetuximab), study participants completed a questionnaire including items regarding usual daily activity level and frequency of participation in recreational physical activity (N = 1,992). Using multivariable Cox models, we calculated HRs for associations of aspects of physical activity with disease-free (DFS) and overall survival (OS).Results: Over follow-up, 505 participants died and 541 experienced a recurrence. Overall, 75% of participants reported recreational physical activity at least several times a month; for participants who reported physical activity at least that often (vs. once a month or less), the HRs for DFS and OS were 0.82 [95% confidence interval (CI), 0.69–0.99] and 0.76 (95% CI, 0.63–0.93), respectively. There was no evidence of material effect modification in these associations by patient or tumor attributes, except that physical activity was more strongly inversely associated with OS in patients with stage T3 versus T4 tumors (Pinteraction = 0.03).Conclusions: These findings suggest that higher physical activity around the time of colon cancer diagnosis may be associated with more favorable colon cancer outcomes.Impact: Our findings support further research on whether colon cancer survival may be enhanced by physical activity. Cancer Epidemiol Biomarkers Prev; 27(6); 696–703. ©2018 AACR.
Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy
Shi, Qian , Taı̈eb, Julien , Meyers, Jeffrey P., Smyrk, Thomas C. , Julié, Catherine , Zawadi, Ayman, Tabernero, Josep , Mini, Enrico , Goldberg, Richard M. , Folprecht, Gunnar , Laethem, Jean Luc Van, Malicot, Karine Le , Laurent‐Puig, Pierre , Zaanan, Aziz , Shi, Qian , Taieb, Julien , Tabernero, Josep , Alberts, Steven R. , Sargent, Daniel J. , Sinicrope, Frank A. , Laurent-Puig, Pierre

JAMA Oncology | October 5, 2017 | Volume: 4 | Issue: 3 | Pages: 379

10.1001/jamaoncol.2017.2899 Get It